X4 Pharmaceuticals Stock Buy Hold or Sell Recommendation
| XFOR Stock | USD 0.52 0.02 4.00% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding X4 Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell X4 Pharmaceuticals given historical horizon and risk tolerance towards X4 Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for X4 Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out X4 Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as XFOR and provide practical buy, sell, or hold advice based on investors' constraints. X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
XFOR |
Execute X4 Pharmaceuticals Buy or Sell Advice
The XFOR recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on X4 Pharmaceuticals. Macroaxis does not own or have any residual interests in X4 Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute X4 Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
X4 Pharmaceuticals Trading Alerts and Improvement Suggestions
| X4 Pharmaceuticals generated a negative expected return over the last 90 days | |
| X4 Pharmaceuticals has some characteristics of a very speculative penny stock | |
| X4 Pharmaceuticals has high historical volatility and very poor performance | |
| X4 Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (101.17 M) with profit before overhead, payroll, taxes, and interest of 3 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (96.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| X4 Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 31897 shares by Paula Ragan of X4 Pharmaceuticals at 0.562 subject to Rule 16b-3 |
X4 Pharmaceuticals Returns Distribution Density
The distribution of X4 Pharmaceuticals' historical returns is an attempt to chart the uncertainty of X4 Pharmaceuticals' future price movements. The chart of the probability distribution of X4 Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use X4 Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of X4 Pharmaceuticals returns is essential to provide solid investment advice for X4 Pharmaceuticals.
| Mean Return | -0.44 | Value At Risk | -11.11 | Potential Upside | 5.41 | Standard Deviation | 4.70 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of X4 Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
XFOR Stock Institutional Investors
The X4 Pharmaceuticals' institutional investors refer to entities that pool money to purchase X4 Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | State Street Corp | 2024-06-30 | 2.8 M | Ensign Peak Advisors Inc | 2024-06-30 | 2.5 M | Sio Capital Management, Llc | 2024-06-30 | 2.5 M | Schonfeld Strategic Advisors Llc | 2024-06-30 | 1.3 M | Ubs O'connor Llc | 2024-06-30 | 1.2 M | Northern Trust Corp | 2024-06-30 | 1.1 M | Parkman Healthcare Partners Llc | 2024-06-30 | 806.6 K | Velan Capital Investment Management Lp | 2024-06-30 | 659 K | Point72 Asset Management, L.p. | 2024-06-30 | 543.1 K | Bain Capital Life Sciences Investors, Llc | 2024-06-30 | 16.9 M | Nea Management Company, Llc | 2024-06-30 | 15 M |
X4 Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 119.6M | (47.4M) | 2.4M | 39.9M | (22.5M) | (21.4M) | |
| Free Cash Flow | (48.2M) | (60.2M) | (71.5M) | (77.2M) | (96.6M) | (91.7M) | |
| Depreciation | 103K | 351K | 499K | 513K | 2.0M | 2.1M | |
| Other Non Cash Items | 8.0M | 7.4M | 19.3M | 5.3M | (5.1M) | (4.9M) | |
| Capital Expenditures | 174K | 1.4M | 615K | 103K | 60K | 57K | |
| Net Income | (52.8M) | (62.1M) | (88.7M) | (93.9M) | (101.2M) | (96.1M) | |
| End Period Cash Flow | 128.1M | 80.7M | 83.1M | 123.0M | 99.5M | 77.3M | |
| Investments | 27.2M | (1.4M) | (615K) | (103K) | (10.1M) | (9.6M) | |
| Net Borrowings | 3.5M | 481K | 12.4M | (795K) | (715.5K) | (679.7K) | |
| Change To Netincome | 7.2M | 6.5M | 19.3M | 6.2M | 7.1M | 6.9M |
X4 Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to X4 Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that X4 Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a XFOR stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 2.40 | |
σ | Overall volatility | 4.68 | |
Ir | Information ratio | -0.11 |
X4 Pharmaceuticals Volatility Alert
X4 Pharmaceuticals exhibits very low volatility with skewness of -0.55 and kurtosis of 1.22. X4 Pharmaceuticals is a potential penny stock. Although X4 Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in X4 Pharmaceuticals. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on XFOR instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.X4 Pharmaceuticals Fundamentals Vs Peers
Comparing X4 Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze X4 Pharmaceuticals' direct or indirect competition across all of the common fundamentals between X4 Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as X4 Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of X4 Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare X4 Pharmaceuticals to competition |
| Fundamentals | X4 Pharmaceuticals | Peer Average |
| Return On Equity | 0.22 | -0.31 |
| Return On Asset | -0.4 | -0.14 |
| Profit Margin | 31.32 % | (1.27) % |
| Operating Margin | (60.21) % | (5.51) % |
| Current Valuation | (6.83 M) | 16.62 B |
| Shares Outstanding | 168.5 M | 571.82 M |
| Shares Owned By Insiders | 1.14 % | 10.09 % |
| Shares Owned By Institutions | 66.35 % | 39.21 % |
| Number Of Shares Shorted | 13.56 M | 4.71 M |
| Price To Book | 0.89 X | 9.51 X |
| Price To Sales | 155.48 X | 11.42 X |
| Gross Profit | 3 M | 27.38 B |
| EBITDA | (107.1 M) | 3.9 B |
| Net Income | (101.17 M) | 570.98 M |
| Cash And Equivalents | 47.38 M | 2.7 B |
| Cash Per Share | 0.69 X | 5.01 X |
| Total Debt | 58.28 M | 5.32 B |
| Debt To Equity | 1.28 % | 48.70 % |
| Current Ratio | 2.39 X | 2.16 X |
| Book Value Per Share | 0.56 X | 1.93 K |
| Cash Flow From Operations | (96.51 M) | 971.22 M |
| Short Ratio | 18.82 X | 4.00 X |
| Earnings Per Share | 0.13 X | 3.12 X |
| Target Price | 4.05 | |
| Number Of Employees | 127 | 18.84 K |
| Beta | 0.36 | -0.15 |
| Market Capitalization | 87.54 M | 19.03 B |
| Total Asset | 147.26 M | 29.47 B |
| Retained Earnings | (477.9 M) | 9.33 B |
| Working Capital | 99.21 M | 1.48 B |
| Net Asset | 147.26 M |
Note: Disposition of 31897 shares by Paula Ragan of X4 Pharmaceuticals at 0.562 subject to Rule 16b-3 [view details]
X4 Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as XFOR . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About X4 Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell X4 Pharmaceuticals? Buying financial instruments such as XFOR Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having X4 Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Heavy Metals Thematic Idea Now
Heavy Metals
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.